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analysis of families in which the incidence of the disease is high. Linkage analysis can reveal the chromosomal location of the genes of interest by identifying polymorphic genetic markers of known location that are coinherited with the disease in families (1) . Among the common cancers, breast cancer is particularly suited for this approach, because family history of the disease is a significant risk factor in all populations; epidemiological evidence consistently indicates that a woman's risk of breast cancer is increased by the occurrence of the disease in her mother or sisters. The younger the ages at diagnosis of her relatives, the greater the increase in a woman's risk (2) .
The transformation of breast ductal epithelial cells to malignant growth results from alterations in their DNA that may be either inherited or somatic (3). Mapping genes for familial breast cancer is important because alterations at the same loci may also be responsible for sporadic disease. Individuals with inherited susceptibility to breast cancer are completely asymptomatic for decades before the onset of disease; the effects of critical inherited alterations are thus latent for an extended period. Among women with no inherited susceptibility to the disease, these same alterations may be the initial lesions of breast tumorigenesis, with disease expression being similarly dependent on subsequent genetic alterations or tumor-promoting steps.
Mapping genes for human breast cancer has been complicated by
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unavoidable epidemiologic realities. The disease is common, but only a small proportion of cases in the general population are attributable to inherited susceptibility. Thus, families may have multiple cases of breast cancer without inherited susceptibility, and "sporadic" cases may occur even in families with inherited disease. In addition, the disease is not completely penetrant among susceptible persons, with expression depending on gender, age, and nongenetic risk factors. Finally, both epidemiological and molecular evidence suggests heterogeneity. We have tested simultaneously for genetic linkage and heterogeneity of breast cancer in families, and our results suggest both the presence of a gene for early-onset breast cancer on chromosome 17q21 and linkage heterogeneity of the disease. Families and inheritance of susceptibility. Our genetic analysis is based on 23 extended families with 146 cases of breast cancer ( Figs. 1 and 2 ). All persons in our analysis are Caucasian and from a variety of original ancestries. The 329 participating relatives now live in, and were therefore sampled from, 40 states of the United States, Puerto Rico, Canada, the United Kingdom, and Colombia. These families share the epidemiological features that are characteristic of familial, versus sporadic, breast cancer (2): younger age at diagnosis, frequent bilateral disease, and more frequent occurrence of disease among men.
Our statistical model for the inheritance of susceptibility to breast cancer was derived from our previous complex segregation analysis of a population-based series of 1500 families with breast cancer (4). Inherited susceptibility to breast cancer in that series could be fully explained by a rare autosomal dominant allele with a major effect on risk: risk of breast cancer in genetically susceptible women was estimated to be 0.37 by age 40, 0.66 by age 55, and 0.82 over the entire lifetime. In contrast, risk of breast cancer in women without genetic susceptibility was estimated to be 0.004 by age 40, 0.028 by age 55, and 0.081 over the entire lifetime. Females less than 15 years of age and all males had a negligible risk (less than 0.001). The estimated proportion of breast cancer cases in the sample that were attributable to inherited susceptibility was only 4 percent, the great majority of cases resulting purely from somatic events. Among younger patients, however, the proportion of inherited cases is likely to be considerably higher. Disease allele frequencies (q) between 0.004 and 0.02 yield virtually identical results; those for q equals 0.01 are described.
Definition of the breast cancer phenotype. For any complex disease, it is essential to adequately define the phenotype, the inheritance of which will be traced in families. Real linkages can be missed and spurious linkages suggested either by defining the phenotype too broadly (so that persons without inherited susceptibility to disease are mistakenly categorized as affected) or simply by making errors in diagnosis. To minimize errors in diagnosis, we reviewed existing pathology records of all family members on whom breast surgery had been performed. 2) In determining a plausible model for inheritance of susceptibility to a complex disease, it is always possible that the underlying genetic model may be correct, but that penetrance may not be accurately estimated. Therefore, we also tested for linkage by including disease information only for the affected relatives (that is, the breast cancer cases) in each family; all unaffected subjects were assigned to the lowest risk class, so that only their marker information was incorporated. Autosomal dominance was still assumed, and lifetime risk of sporadic disease was not altered.
3) In order to evaluate linkage without imposing any specific genetic model, we counted alleles shared by descent for affected pairs of female relatives. This analysis was possible because one marker was highly polymorphic. Pairs of affected relatives were sisters (firstdegree relatives), aunt-niece and grandmother-granddaughter (second-degree relatives), and first cousins. (third-degree relatives). Relative pairs were stratified by the average age of breast cancer diagnosis for the pair.
4) We applied the affected-pedigree-member method to evaluate sharing of alleles by state among the breast cancer cases in each family (7). Only cases whose marker genotypes could be determined with certainty were included in the analysis of affected pedigree members.
Typing of DNA polymorphisms. For each of the 329 informative relatives, we obtained 35 milliliters of fresh blood and prepared immortalized lymphocytes by Epstein-Barr viral transformation (8). Genomic DNA was prepared as described (9) . Probes were labeled by random primer extension (10) frequencies of the D17S74 alleles in this sample were estimated by selecting subjects from different families whose D17S74 fragments appeared to be of similar size on the basis of their "family blots," and then analyzing the DNA from these unrelated persons in neighboring lanes on the same blots. Some samples were included several times in order to identify distortions in the gels. These "population blots" were analyzed without reference to sample numbers, in order to determine which alleles could be consistently distinguished. D17S74 had more than 30 distinguishable fragment lengths-and hence more than 30 different alleles-in our sample, nine of which occurred more than once among unrelated individuals, at frequencies ranging from 0.07 to 0.13. The other D17S74 alleles were only represented once in our sample, but because extremely rare marker allele frequencies can have a major influence on estimates of lod scores and the T statistic (7), apparently unique alleles were each assigned the frequency 0.03. Results of linkage and heterogeneity analysis in the breast cancer families. For the 23 families as a group, homogeneity of linkage of breast cancer to D17S74 could be rejected at P equals 0.01. Multipoint analysis of linkage in the interval D17S78-D17S41-D17S74-D17S40 yielded likelihood ratios in favor of heterogeneity of linkage among the 23 families between 2000:1 and 1.4 x 106 to 1. After adjusting for heterogeneity among all families, the maximum two-point lod score is + 3.28 at recombination distance of 0.014 from D17S74, with disease linked to this locus in 40 percent of the families (Figs. 1 and 2) .
Heterogeneity of linkage in these families appears explicable by age of disease onset. Breast cancer is linked to markers in this chromosomal region specifically in families with early-onset breast cancer. Among the seven families with a mean age of breast cancer diagnosis less than or equal to 45, the two-point lod score for linkage of D17S74 and breast cancer is +5.98 at a distance of 0.001 recombination units, with a 95 percent confidence interval of 0.001 to 0.09 (Table 1 ). In contrast, total lod scores for the families with late-onset disease are negative. It is characteristic of linkage in the presence of heterogeneity that a modest lod score (in this case +2.35) for all families, ignoring heterogeneity, at a fairly large recombination distance (0.20 recombination units) masks two curves, one with a more positive lod score in the linked families (+5.98) at a smaller recombination fraction (0.001 to 0.09) and the other negative (15) . Two-point lod scores for all four markers in this chromosomal region suggest that a gene for susceptibility in the early-onset families is likely to be within approximately 10 percent recombination of D1 7S74 (Table 2 ). Multipoint analysis of the fourmarker interval yields a maximum lod score of + 5.41 near D17S74 for the earliest-onset families (Table 2) . Again, total lod scores for families with older ages at diagnosis are negative throughout the interval.
Linkage of breast cancer to D17S74 was also evaluated on the basis of only the individuals with breast cancer in each family. For this analysis, all women without breast cancer and all men were assigned to the lowest risk group. For the 23 families as a group, the P value for homogeneity of linkage is 0.06. For the families with average age at diagnosis less than or equal to 45, the maximum lod score is +4.69 at close linkage, with a 95 percent confidence interval for the recombination fraction of 0.001 to 0.10. Lod scores at close linkage to D17S74 are -2.19 for families 8 to 15 and -5.22 for families 16 to 23.
Analysis of alleles shared by descent among related pairs of women with breast cancer also suggested linkage of early-onset breast cancer to D1 7S74 (Table 3 ). In families 1 to 7, all three classes of relatives shared more alleles by descent than expected by chance. Even in families 8 to 23, there was evidence for increased identity by descent among sisters with early-onset disease, but little or no evidence for increased identity by descent for second-and thirddegree relatives. Finally, the affected-pedigree-member analysis of alleles shared by state among all individuals with breast cancer in each family also suggested linkage of early-onset breast cancer to markers in this chromosomal region (16). These analyses defined families with early-onset disease as those with an average age at breast cancer diagnosis of less than or equal to 45. However, "early-onset" could be defined in a variety of ways. The cumulative lod scores for linkage of breast cancer to D1 7S74, as families with increasing age at disease onset are included in the analysis, are indicated in Fig. 3 and the right-hand column of Table  1 . Cumulative lod scores are above 5.0 for families with an average age at diagnosis of less than 48, remain positive for families with an average age at diagnosis of less than 52, and then drop sharply. As specific alternative ways of defining early-onset breast cancer, we defined families with early-onset disease to be those in which (i) most breast cancers in each family were diagnosed by age 50 (families 1 to 7, 9, 10, 12, 13, 21) , or (ii) most breast cancers in each family were diagnosed by age 45 (families 1 to 6, 10), or (iii) the average age at breast cancer diagnosis was less than 48, the mean for all the cases in the sample (families 1 to 10). The critical results for all definitions were the same: maximum lod scores for linkage of breast cancer to this chromosomal region are between 5.2 and 5.7 in the early-onset families and negative in the late-onset families, and the disease gene appears to be within about 0.10 recombinatioi units of D17S74.
Other risk factors for breast cancer in the families. To determine whether the linked gene is expressed in the presence of any specific background of nongenetic risk factors for breast cancer, we compared breast cancer risk factors for women in families with apparent linkage of breast cancer to chromosome 17q versus women in families with evidence against this linkage. Ages at first pregnancy, number of children, prevalence of fertility problems, exposure to x-rays, use of oral contraceptives, and ages at menopause were similarly distributed in "linked" and "unmlinked"' families, after adjusting for age and birth cohort of the women. Similarly, preva- (17) . An earlier linkage analysis from our group, based on fewer and less-informative families, suggested (with a modest lod score) that a gene for familial premenopausal breast cancer or ovarian cancer is present on chromosome 16q (18) . We have excluded the other regions suggested by loss of heterozygosity in tumors as locales of genes for inherited susceptibility to breast cancer (9, 19) .
A gene or genes on chromosome 5q appear to be responsible for inherited forms of colon cancer and quite possibly for the initial somatic lesions of other colon cancers, with genes on 12p (K-ras), 17p (p53), 18q (DCC), and possibly elsewhere being responsible for subsequent invasion and metastasis (20) . This pattern of multiple sequential events, determined by alterations on more than one chromosome, may also apply to breast cancer.
Negative lod scores in the families with late-onset breast cancers may reflect any or all of the following: the existence of a different locus or loci responsible for inherited susceptibility in these families; the chance occurrence of some families with multiple cases; or a (MIM 190150) . The gene her2 acts as an oncogene in NIH 3T3 cells and is amplified in many primary breast tumors; her2 amplification is associated with poor prognosis at least for nodepositive tumors (22) . Other candidate genes in this region include that for estradiol-17P dehydrogenase (edhbl7; MIM 264300), which is the enzyme that catalyzes the conversion of estrone to estradiol; the homeobox 2 gene (hox2; MIM 142960), which is critical for murine embryological development; nm23, whose expression is associated with lymph node metastasis in primary breast carcinomas; the gene for retinoic acid receptor ax (rara; MIM 180240), a protein that binds the possible anticarcinogen retinoic acid; and wnt3 (MIM 165330), one of the integration sites activated by the mouse mammary tumor virus and which is homologous to the Drosophila winglessness locus (23) . If alterations in any of these genes are responsible for inherited breast cancer, polymorphisms at the critical locus may be in linkage disequilibrium with the disease in the early-onset families.
